These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 12056921)

  • 21. Quality of life and subjective well-being during treatment with antipsychotics in out-patients with schizophrenia.
    Wehmeier PM; Kluge M; Schneider E; Schacht A; Wagner T; Schreiber W
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Apr; 31(3):703-12. PubMed ID: 17289237
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Metabolic side effects of risperidone in early onset schizophrenia].
    Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
    Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clozapine in schizophrenia and its association with treatment satisfaction and quality of life: Findings of the three national surveys on use of psychotropic medications in China (2002-2012).
    Li Q; Xiang YT; Su YA; Shu L; Yu X; Correll CU; Ungvari GS; Chiu HF; Ma C; Wang GH; Bai PS; Li T; Sun LZ; Shi JG; Chen XS; Mei QY; Li KQ; Si TM; Kane JM
    Schizophr Res; 2015 Oct; 168(1-2):523-9. PubMed ID: 26277534
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 25. What are the therapeutic needs in schizophrenia and how are they satisfied by new antipsychotics?
    Kane JM
    Int Clin Psychopharmacol; 1997 May; 12 Suppl 2():S3-6. PubMed ID: 9218161
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patients' opinions of olanzapine and risperidone following long-term treatment: results from a cross-sectional survey.
    McGrath BM; Tempier RP
    Pharmacopsychiatry; 2005 Jul; 38(4):147-57. PubMed ID: 16025416
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fewer symptoms vs. more side-effects in schizophrenia? Opposing pathways between antipsychotic medication compliance and quality of life.
    Staring AB; Mulder CL; Duivenvoorden HJ; De Haan L; Van der Gaag M
    Schizophr Res; 2009 Aug; 113(1):27-33. PubMed ID: 19525092
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New antipsychotics, compliance, quality of life, and subjective tolerability--are patients better off?
    Awad AG; Voruganti LN
    Can J Psychiatry; 2004 May; 49(5):297-302. PubMed ID: 15198465
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Subjective response to antipsychotics in schizophrenic patients: clinical implications and related factors.
    Cabeza IG; Amador MS; López CA; González de Chávez M
    Schizophr Res; 2000 Jan; 41(2):349-55. PubMed ID: 10708344
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Good tolerability equals good results: the patient's perspective.
    Naber D; Karow A
    Eur Neuropsychopharmacol; 2001 Oct; 11 Suppl 4():S391-6. PubMed ID: 11587886
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Flupenthixol versus risperidone: subjective quality of life as an important factor for compliance in chronic schizophrenic patients.
    Hertling I; Philipp M; Dvorak A; Glaser T; Mast O; Beneke M; Ramskogler K; Saletu-Zyhlarz G; Walter H; Lesch OM
    Neuropsychobiology; 2003; 47(1):37-46. PubMed ID: 12606844
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [If drugs are not taken - how different antipsychotics influence compliance of schizophrenic patients].
    Schorr SG; Brouwers JR; Taxis K
    Fortschr Neurol Psychiatr; 2007 Aug; 75(8):473-7. PubMed ID: 17638181
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A survey of patient satisfaction with and subjective experiences of treatment with antipsychotic medication.
    Gray R; Rofail D; Allen J; Newey T
    J Adv Nurs; 2005 Oct; 52(1):31-7. PubMed ID: 16149978
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Estimated dopamine D2 receptor occupancy from plasma concentrations of atypical antipsychotics and subjective experience/drug attitude in schizophrenia: an analysis of the CATIE data.
    Takeuchi H; Suzuki T; Bies RR; Remington G; Mamo DC; Pollock BG; Mimura M; Uchida H
    Schizophr Res; 2013 Nov; 150(2-3):373-9. PubMed ID: 24028745
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
    Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
    J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of antipsychotic side effects on attitudes towards medication in people with schizophrenia and related disorders.
    Chiang YL; Klainin-Yobas P; Ignacio J; Chng CM
    J Clin Nurs; 2011 Aug; 20(15-16):2172-82. PubMed ID: 21539628
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment adherence and insight in schizophrenia.
    Bitter I; Fehér L; Tényi T; Czobor P
    Psychiatr Hung; 2015; 30(1):18-26. PubMed ID: 25867885
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Measuring adherence to medication in schizophrenia: the relationship between attitudes toward drug therapy and plasma levels of new-generation antipsychotics.
    Yalcin-Siedentopf N; Wartelsteiner F; Kaufmann A; Biedermann F; Edlinger M; Kemmler G; Rettenbacher MA; Widschwendter CG; Zernig G; Fleischhacker WW; Hofer A
    Int J Neuropsychopharmacol; 2014 Dec; 18(5):. PubMed ID: 25522423
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of life.
    Lambert M; Naber D
    CNS Drugs; 2004; 18 Suppl 2():5-17; discussion 41-3. PubMed ID: 15461312
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
    Jones PB; Barnes TR; Davies L; Dunn G; Lloyd H; Hayhurst KP; Murray RM; Markwick A; Lewis SW
    Arch Gen Psychiatry; 2006 Oct; 63(10):1079-87. PubMed ID: 17015810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.